IGT Webinar on CMS Proposed Rule on Value-based Purchasing

On Monday, July 13, the Institute for Gene Therapies (IGT) held a conversation with recognized experts on the CMS proposed rule that makes changes to the Medicaid Drug Rebate Program (MDRP) to facilitate value-based purchasing (VBP) arrangements.


Speakers included:

  • Stuart Portman, Health Policy Advisor, U.S. Senate Finance Committee

  • Mark Trusheim, Strategic Director, MIT NEWDIGS

  • Annie Kennedy, Chief of Policy and Advocacy, EveryLife Foundation for Rare Diseases

  • Thomas Evegan, VP, Integrichain

  • Lauren Randall Buckley, Director of Health Policy & Advocacy, IGT

View the full discussion below:



high res logo.png

The Institute for Gene Therapies advocates for a modernized regulatory and reimbursement framework that encourages the development of transformative gene therapies and promotes patient access. 

Get In Touch

IGT. © 2020 All Rights Reserved